Premier Research: holistic approach benefits development
Oct 6, 2020 · Holistic design starts off with designing a target product profile that considers the end goal early in the development planning. Also, part of a successful holistic approach, Sharif suggested, is asking thoughtful, appropriate questions at the outset, making sure to consider outcome-focused impactful issues at every stage of development.
Blood-based Alzheimer’s test set to revolutionize early diagnosis
Aug 27, 2024 · This antibody is integral to advanced blood-based tests that are transforming Alzheimer’s diagnosis, treatment, and real-time disease monitoring. Our collaboration with Beckman Coulter aims to democratize access to the pTau217 antibody, developing it into a highly accurate blood-based test on the DxI 9000 analyzer.
AI-enabled platform by Creyon Bio receives second US Patent
Sep 10, 2024 · Creyon Bio secures second patent for AI-powered oligonucleotide engineering. Creyon Bio Inc., a clinical-stage biotechnology company specializing in AI and machine learning-enabled oligonucleotide-based medicines (OBMs), recently announced the issuance of its second US patent. This patent protects the company’s proprietary Creyon platform ...
Lonza, Vineti team up to address risks in the ‘vein-to-vein’ supply …
Aug 1, 2019 · Lonza, Vineti team up to address risks in the ‘vein-to-vein’ supply chain. Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development. Lonza entered the non-exclusive business collaboration in an aim to ...
Streamlining healthcare supply chains: TraceLink teams up with …
Aug 14, 2024 · By integrating our multi-enterprise digital network platform with Tecsys' robust inventory and warehouse management functionality, we can provide real-time supply chain information that enhances patient care while reducing administrative burdens.”. For TraceLink, this collaboration is more than just a tactical move—it aligns with the ...
ICON to acquire PRA Health Sciences in $12b deal
Feb 25, 2021 · ICON, a Dublin-based contract research organization (CRO) has entered into an agreement to acquire PRA Health Sciences, another CRO currently sited in Raleigh, North Carolina. The arrangement comprises a cash and stock transaction valued at approximately $12bn USD. According to company leaders, the transaction stands to benefit pharmaceutical ...
Ukraine war offers hard lessons for clinical research industry: H1
Mar 29, 2022 · Outsourcing-Pharma recently connected with Ariel Katz, founder and CEO of healthcare technology provider H1, about the far-reaching impact Russia’s attack on Ukraine is having on the industry. He also offers suggestions as to how clinical trial professionals and pharmaceutical companies can work to mitigate the effects of both human-made and ...
ANI Pharmaceuticals acquires Amerigen’s commercial products
Jan 13, 2020 · ANI acquires the 23 generic products from Amerigen to expand its commercial offering in the US. The deal sees ANI Pharmaceuticals pay $52.5m (€47.2m) Amerigen Pharmaceuticals in cash, with an additional $25m in contingent profit share payments to be made over the next four years. Through the deal, ANI will take responsibility for 10 ...
How SOMS is shaping the future of clinical trials
Sep 5, 2024 · The future of clinical trial optimization, particularly with AI-driven tools like SOMS, is on the cusp of significant advancements. Upcoming enhancements aim to integrate SOMS seamlessly with other technologies, such as data management systems, enabling real-time analysis and dynamic trial management. The incorporation of SOMS into risk-based ...
Slope unveils tech-enabled solutions to optimize clinical trial data
Sep 11, 2024 · Slope says its tech-enabled services provide a cost-effective, high-impact solution for pharmaceutical companies facing the growing complexities of sample-intensive trials. By combining its core product, Biospecimen360, with expert support, the company says it empowers clinical trial sponsors to unlock the full potential of their biospecimen data.